Thermochemical ablation system using heat from delivery of electrophiles

• US 8,979,831 B2
• Filed: 07/29/2009
• Issued: 03/17/2015
• Est. Priority Date: 07/31/2008
• Status: Active Grant

• Current Assignee: Regents of The University of Minnesota (University of Minnesota)
• Original Assignee: Regents of The University of Minnesota (University of Minnesota)
• Inventors: Cressman, Erik N. K.
• Primary Examiner(s): Dvorak, Linda
• Assistant Examiner(s): Ram, Jocelyn D
• Application Number:
  US13/056,376
• Publication Number:
  US 20110152852A1
• Time in Patent Office: 2,057 Days
• Field of Search: 606/27, 606/28, 604/82, 604/113, 604/257, 604/506
• US Class Current: 606/27
• CPC Class Codes: A61B 18/06 caused by chemical reaction , e.g. moxaburners
• CPC Class Codes: A61B 2018/00577 Ablation
• CPC Class Codes: A61B 2018/068 none of the reactants being oxygen
• CPC Class Codes: A61B 2018/1425 Needle
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61M 2025/0037 characterized by lumina being arranged side-by-side
• CPC Class Codes: A61M 25/003 characterized by features relating to least one lumen located at the distal part of the catheter, e.g. filters, plugs or valves catheter tips A61M25/0067

Abstract

Thermochemical ablation techniques may provide ablation of bodily tissue using chemical reaction energy. The chemical reaction energy is provided by chemical reactions including a highly reactive electrophilic reagent provided to a target tissue location.

Claims

1. A thermochemical ablation system, comprising:

a percutaneous fluid delivery cannula comprising a first lumen extending from a proximal portion to a distal portion, the distal portion comprising a first port in fluid communication with at least the first lumen;

a first reservoir containing a highly reactive electrophilic reagent in fluid communication with the first lumen of the percutaneous fluid delivery cannula, at least a portion of the highly reactive electrophilic reagent being deliverable out of the first port to locally generate ablation heat at a targeted site and to provide a localized residual acidic environment at the targeted site for a period of time after generation of the ablation heat; and

a real-time imaging system that monitors the distal portion of the percutaneous fluid delivery cannula and the delivery of the highly reactive electrophilic reagent.

2. The system of claim 1, wherein the percutaneous fluid delivery cannula comprises a generally rigid injection needle.

3. The system of claim 2, wherein the injection needle comprises an outside diameter of about 0.134 inches or less.

4. The system of claim 1, wherein the highly reactive electrophilic reagent is deliverable from the first port so as to react with nucleophiles inherently present at the targeted site to locally generate ablation heat sufficient to ablate bodily tissue proximate the distal portion of the percutaneous fluid delivery cannula.

5. The system of claim 4, wherein the nucleophiles inherently present at the targeted site comprise naturally occurring proteins disposed in the bodily tissue.

6. The system of claim 1, further comprising:

a second lumen extending from a proximal portion of the percutaneous delivery cannula to a distal portion of the cannula, the distal portion comprising a second port in fluid communication with at least the second lumen; and

a second reservoir to communicate a nucleophile reagent through the second lumen to the distal portion of the percutaneous fluid delivery cannula, at least a portion of the nucleophile reagent being deliverable out of the second port prior to delivery of the highly reactive electrophilic reagent out of the first port.

7. The system of claim 6, wherein the nucleophile reagent is delivered from the second port first in order to pre-treat the targeted site, and the highly reactive electrophilic reagent is subsequently delivered from the first port so that the reagents mix with one another at the targeted site to locally generate an exothermic chemical reaction.

8. The system of claim 7, wherein the exothermic chemical reaction generates heat sufficient to ablate bodily tissue proximate the distal portion of the percutaneous fluid delivery cannula.

9. The system of claim 1, wherein the highly reactive electrophilic reagent comprises a carboxylic acid anhydride or halide.

10. The system of claim 9, wherein the nucleophile reagent comprises a base.

11. The system of claim 1, wherein the percutaneous fluid delivery cannula comprises a flexible catheter.

12. A method for thermochemical ablation of targeted tissue, comprising:

delivering a highly reactive electrophilic reagent through a lumen of a percutaneous injection needle to a targeted tissue site; and

reacting the delivered electrophilic reagent with nucleophiles at the targeted tissue location to locally generate ablation heat at the targeted tissue site and to provide a localized residual acidic environment at the targeted tissue site for a period of time after generation of the ablation heat.

13. The method of claim 12, wherein the highly reactive electrophilic reagent is delivered from one or more side ports of the injection needle.

14. The method of claim 12, wherein the highly reactive electrophilic reagent comprises a carboxylic acid anhydride.

15. The method of claim 12, wherein the highly reactive electrophilic reagent comprises acetic anhydride.

16. The method of claim 12, wherein the highly reactive electrophilic reagent comprises a carboxylic halide.

17. The method of claim 12, wherein the highly reactive electrophilic reagent comprises an acetyl halide.

18. The method of claim 12, wherein the highly reactive electrophilic reagent comprises acetyl chloride.

19. The method of claim 12, wherein the highly reactive electrophilic reagent comprises a sulfonyl acid anhydride or halide.

20. The method of claim 12, wherein the highly reactive electrophilic reagent comprises a phosphonyl acid anhydride or halide.

21. The method of claim 12, wherein the highly reactive electrophilic reagent further comprises a diagnostic group usable for imaging or tracing purposes.

22. The method of claim 12, wherein the highly reactive electrophilic reagent comprises one or more electrophilic leaving group species.

23. The method of claim 12, wherein the highly reactive electrophilic reagent comprises one or more diagnostic leaving groups usable for imaging or tracing purposes.

24. The method of claim 12, further comprising delivering a nucleophile reagent to the targeted tissue site prior to delivering the highly reactive electrophilic reagent to the targeted tissue site.

25. The method of claim 24, wherein the nucleophile reagent comprises a base.

26. The method of claim 25, wherein the nucleophile reagent comprises a base selected from the group consisting of KOH, NaOH, NH₄OH, Ca(OH)₂, NaHCO₃, K₂CO₂, BuLi, NaOEt or NaSEt, amines, and combinations thereof.

27. The method of claim 12, further comprising delivering an inert, non-reactive agent to the targeted tissue site.

28. The method of claim 27, wherein the inert, non-reactive agent comprises a diagnostic agent.

29. The method of claim 12, further comprising monitoring the targeted tissue site with real-time imaging.

30. The method of claim 29, wherein real-time imaging comprises CT, ultrasound, MRI, or other imaging system.

31. A method for thermochemical ablation of targeted tissue, comprising delivering a highly reactive electrophilic reagent to a targeted tissue to generate heat in a localized area in order to ablate the targeted tissue area.

32. The method of claim 31, wherein the highly reactive electrophilic reagent comprises an inorganic or organic chloride.

33. The method of claim 31, wherein the highly reactive electrophilic reagent comprises an inorganic acid halide.

34. The method of claim 31, wherein the highly reactive electrophilic reagent comprises acetyl chloride.

35. The method of claim 31, wherein the highly reactive electrophilic reagent comprises ethyl chloroformate.

36. The method of claim 31, further comprising pre-treating the targeted tissue area with a nucleophilic reagent.

37. The method of claim 36, wherein the nucleophilic reagent comprises an inorganic or organic base.

38. The method of claim 36, wherein the nucleophilic reagent comprises sodium hydroxide or potassium hydroxide.